.png){kind=icon}
Return
Thalassaemia
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-026-00722-w.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The thalassaemia syndromes, which primarily include α-thalassaemia and β-thalassaemia, are a complex group of inherited disorders affecting haemoglobin production. They are prevalent throughout the most populated parts of the world and span a wide range of severity from mild to fatal. Advances in the management of these syndromes, including blood transfusion and iron chelation, have led to substantial improvements in the life expectancy and quality of life of many patients worldwide. Nevertheless, major forms of thalassaemia are still associated with chronic comorbidities and remain an important but neglected global health burden. Prevention and advances in the treatment and management of the thalassaemia syndromes rely on the early identification of people affected, either through prenatal or premarital screening or through newborn screening or testing at later stages in life. This depends on the availability of expertise, facilities and treatment options for patients. Fast and groundbreaking developments in disease-modifying and curative gene editing therapies are promising, but not without challenges in terms of costs, accessibility and uncertainties around their long-term benefits and safety. Better awareness, patient-centred approaches and coordinated strategies are needed to reduce current inequalities. The thalassaemia syndromes are genetic disorders that affect the production of normal haemoglobin. In this Primer, Piel and colleagues describe the epidemiology of the thalassaemia syndromes; discuss their mechanisms, diagnosis and management; and highlight patients’ quality of life and questions for future research.
Journal
N
IF:
60.6
Papers:
650
Citations:
3.8W
Organization
B
View more organizations
Cited Papers
Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis.png)
Blood
BloodIF0
PREAI
ShareSaveNovel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disordersBlood
OAAI
BloodIF0
OAAIShareSaveDurable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaBLOOD
BLOODIF23.1
PREAI
ShareSaveThe Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International FederationHemoglobin
HemoglobinIF0
PREAI
ShareSaveShareSaveIncreasing prevalence of thalassemia in America: Implications for primary careANNALS OF MEDICINEOAAI
ANNALS OF MEDICINEIF4.3
OAAIShareSaveGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell diseaseBlood
OAAI
BloodIF0
OAAIShareSave View more